Sponsored by
This post hoc analysis looked at the effect of temozolomide (TMZ) timing on glioblastoma outcomes using data from two past clinical trials: the CENTRIC trial (for MGMT methylated patients) and the CORE trial (for MGMT unmethylated patients). Due to EU patient data regulations, only patients from the studies who were deceased at the time of database closure (April 1, 2024) were included in the analysis (i.e., 72% of patients from CENTRIC and 75% of patients from CORE). In CENTRIC, median overall survival (mOS) was 20.6 months for morning TMZ versus 21.1 months for evening TMZ. In CORE, mOS was 10.9 months for morning TMZ versus 11.4 months for evening TMZ. These differences were not statistically significant. However, morning TMZ administration was associated with higher bone marrow toxicity in both trials. Although this analysis found no survival benefit based on TMZ timing, these results should only be considered exploratory, and not definitive, due to the study limitations.